Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Tenascin-C triggers fibrin accumulation by downregulation of tissue plasminogen activator.

Brellier F, Hostettler K, Hotz HR, Ozcakir C, Çöloğlu SA, Togbe D, Ryffel B, Roth M, Chiquet-Ehrismann R.

FEBS Lett. 2011 Mar 23;585(6):913-20. doi: 10.1016/j.febslet.2011.02.023. Epub 2011 Feb 24.

2.

Gene expression profiling of cathepsin D, metallothioneins-1 and -2, osteopontin, and tenascin-C in a mouse spinal cord injury model by cDNA microarray analysis.

Hashimoto M, Koda M, Ino H, Yoshinaga K, Murata A, Yamazaki M, Kojima K, Chiba K, Mori C, Moriya H.

Acta Neuropathol. 2005 Feb;109(2):165-80. Epub 2004 Dec 9.

PMID:
15592854
3.
5.

Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.

Diamond MP, Kruger M, Saed GM.

Fertil Steril. 2004 Jun;81(6):1657-64.

PMID:
15193491
6.

Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative regulators in fibroblasts.

Sakai T, Furukawa Y, Chiquet-Ehrismann R, Nakamura M, Kitagawa S, Ikemura T, Matsumoto K.

J Cell Sci. 1996 Aug;109 ( Pt 8):2069-77.

7.
9.
10.
11.

Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.

Rakic JM, Lambert V, Munaut C, Bajou K, Peyrollier K, Alvarez-Gonzalez ML, Carmeliet P, Foidart JM, Noël A.

Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1732-9.

PMID:
12657615
12.

Fibrin-induced skin fibrosis in mice deficient in tissue plasminogen activator.

de Giorgio-Miller A, Bottoms S, Laurent G, Carmeliet P, Herrick S.

Am J Pathol. 2005 Sep;167(3):721-32.

13.

Differences in the expression of genes between normal tissue and squamous cell carcinomas of head and neck using cancer-related gene cDNA microarray.

Kainuma K, Katsuno S, Hashimoto S, Oguchi T, Suzuki N, Asamura K, Usami S.

Acta Otolaryngol. 2006 Sep;126(9):967-74.

PMID:
16864496
14.

c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells.

Hou Y, Okamoto C, Okada K, Kawao N, Kawata S, Ueshima S, Matsuo O.

Cardiovasc Res. 2007 Jul 1;75(1):186-94. Epub 2007 Mar 3.

15.

Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL.

Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5899-904.

16.

Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice.

Okada K, Fujita T, Minamoto K, Liao H, Naka Y, Pinsky DJ.

J Biol Chem. 2000 Jul 14;275(28):21468-76.

17.

Adenoviral-mediated expression and local deposition of recombinant tenascin-C perturbs cell-dependent matrix contraction.

Hsia HC, Schwarzbauer JE.

J Surg Res. 2006 Nov;136(1):92-7. Epub 2006 Aug 22.

PMID:
16926030
18.

Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.

Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA.

Laryngoscope. 2004 Dec;114(12):2063-72.

PMID:
15564824
19.

Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.

Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, Carmeliet P, Weiss MH, Zlokovic BV.

Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2801-6.

20.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk